05:18 , Apr 26, 2019 |  BC Week In Review  |  Financial News

Nanjing Leads closes series A for immuno-oncology programs

Nanjing Leads raised about RMB100 million ($14.9 million) in a series A round to advance its immuno-oncology programs into the clinic. Existing investors CCB Capital, Ennovation Ventures and New Vision Ventures participated, along with new...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
19:11 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Mouse studies suggest inhibiting FACT (facilitates chromatin transcription), a heterodimer consisting of SSRP1 and SUPT16H subunits, in combination with chemotherapy could help treat small cell lung cancer (SCLC). In three...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

Entolimod: Phase II started

Cleveland BioLabs began a single-blind, placebo-controlled, Russian Phase II trial to evaluate entolimod in up to 32 treatment-naive patients recommended for surgery. Patients will receive an injection of 0.35 or 0.45 ug/kg entolimod 5 days...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

CBLB612: Phase II started

Cleveland began a placebo-controlled, Russian Phase II trial to evaluate a single dose of CBLB612 given before or after chemotherapy with doxorubicin and cyclophosphamide in at least 39 breast cancer patients. The study is supported...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Financial News

Cleveland BioLabs withdraws follow-on

Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y.   Business: Cancer, Other, Hematology   Date announced: 2015-11-04   Type: Follow-on   Underwriter: Ladenburg Thalmann   Note: Cleveland BioLabs withdrew its proposed follow-on. The company filed to raise...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Protectan CBLB612: Phase I data

A single-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single subcutaneous injections of 0.5-4 ug CBLB612 were generally well tolerated. The MTD was 4 ug CBLB612. CBLB612 also led to dose-dependent increases...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

Cancer INDICATION: Lung cancer In vitro and mouse studies suggest TRAIL plus inhibition of either NF-κB, miR-21, miR-30c or miR-100 could help treat TRAIL-resistant lung cancer. Levels of NF-κB, miR-21, miR-30c and miR-100 were higher...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Cleveland BioLabs, Bioprocess Capital Ventures deal

Cleveland sold 75% of its equity stake in Incuron for about $3 million to Dr. Mikhail Mogutov, who is the chairman of Incuron. Mogutov has an option to purchase Cleveland’s remaining stake for $1 million....
07:00 , Jun 29, 2015 |  BC Week In Review  |  Financial News

Cleveland BioLabs completes private placement

Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y.   Business: Cancer, Other, Hematology   Date completed: 2015-06-25   Type: Private placement   Raised: $25 million   Shares: 6.5 million   Price: $3.87   Shares after offering: 10.5...